Compare Abbott Laboratories (ABT) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Mega Cap Growth ETF — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Vanguard Mega Cap Growth ETF trades at $87.2. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Mega Cap Growth ETF pays none, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | MGK | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $92.06 |
52-Week Low | $82.57 | $70.70 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MGK trades at $88.29, up 1.47% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF completed a 1:5 stock split in April 2026 and announced a $0.08 dividend for H1-2026. News highlights potential inclusion of SpaceX and emphasizes MGK's low 0.05% expense ratio and heavy concentration in mega-cap tech stocks, which have driven historical outperformance versus the S&P 500.
Outlook remains positive due to exposure to high-growth tech giants, though concentration risk and overbought technicals near-term pose challenges. Long-term growth potential is supported by earnings momentum, but investors face volatility from sector rotations and valuation sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
